Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Neuromuscular
How could you utilize neuromuscular ultrasound as a marker of disease progression/treatment response in CIDP?
Related Questions
What is the role of skin biopsy for evaluating small fiber neuropathy in patients with rheumatic disease who have treatment recalcitrant pain?
How do you adjust chronic outpatient steroid therapy when myasthenia gravis patients are admitted for crisis?
How do you approach weaning treatments for CIDP in remission?
Do you perform EMG and repetitive nerve stimulation in patients with ocular myasthenia gravis, particularly those who are AChR-positive, to assess for electrophysiological evidence of generalized disease?
In which clinical scenarios do you find medial and lateral plantar sensory or mixed nerve conduction studies to be valuable?
What is your approach to managing seronegative myasthenia gravis in patients who have not responded to immunotherapy?
Which methods of tracking response to treatment in myasthenia gravis do you find most helpful?
How do you approach sequentially tapering combination therapy (i.e., IVIG, mycophenolate, rituximab) for dermatomyositis that is in remission?
When and how do you perform genetic testing for congenital myasthenia gravis in seronegative cases?
What types of cardiac conduction abnormalities would lead you to avoid using tricyclic antidepressants?
